Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00665665 · ClinicalTrials.gov registry record · Phase 1
Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 101
- Enrollment target
NCT00665665 is a Phase 1 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 101 participants.
The verdict
NCT00665665, a Phase 1 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 101 participants
- Enrollment target
Study Summary
This trial will be conducted in the United States of America (USA). The aim of the trial is to investigate whether the drug is safe, well tolerated and to investigate the efficacy of NNC 0070-0002-0182 for the treatment of obesity. The subjects will be treated with drug and placebo. This registration covers the phase 2 part of a combined phase 1/phase 2 trial (phase 1 part of trial conducted between November 2007 and April 2008).
Interventions
- DRUG placebo
- DRUG NNC 0070-0002-0182
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00665665
The ClinicalTrials.gov registry entry for NCT00665665 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00665665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00665665 about?
NCT00665665 is a clinical study titled "Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers". This trial will be conducted in the United States of America (USA). The aim of the trial is to investigate whether the drug is safe, well tolerated and to investigate the efficacy of NNC 0070-0002-0182 for the treatment of obesity. The subjects will be treated with drug and placebo. This registratio...
What is the current status of trial NCT00665665?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 101 participants. The study started on 2007-11. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00665665?
The interventions under investigation include: placebo (DRUG), NNC 0070-0002-0182 (DRUG).
Who is sponsoring clinical trial NCT00665665?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.